Segment Information - Reportable Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net sales:
Net sales	$ 2,899	$ 3,027
Segment Adjusted Operating EBITDA:
Adjusted Operating EBITDA	578	503
Other Depreciation and Amortization	278	276
Interest expense	(83)	(100)
Other income, net	(1)	(17)
Restructuring and other charges, net	(3)	(52)
Acquisition, divestiture, and integration related costs	58	31
Tax realignment costs	(1)	0
Strategic initiative costs	(4)	(13)
Regulatory costs	(35)	(5)
Other gains (losses)	0	(5)
Income before taxes	115	14
Business divestiture costs	(56)	(21)
Integration-related costs	(2)	(10)
Nourish
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(2)	(30)
Health & Biosciences
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	(1)	(10)
Scent
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	0	(10)
Pharma Solutions
Segment Adjusted Operating EBITDA:
Restructuring and other charges, net	0	(2)
Operating Segments | Nourish
Net sales:
Net sales	1,496	1,653
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	216	208
Operating Segments | Health & Biosciences
Net sales:
Net sales	531	513
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	159	131
Operating Segments | Scent
Net sales:
Net sales	645	608
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	157	105
Operating Segments | Pharma Solutions
Net sales:
Net sales	227	253
Segment Adjusted Operating EBITDA:
Segment Adjusted Operating EBITDA	$ 46	$ 59